Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKX1 | ISIN: SE0012570448 | Ticker-Symbol: 5J6
Tradegate
02.07.25 | 12:33
1,330 Euro
-0,89 % -0,012
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
OSSDSIGN AB Chart 1 Jahr
5-Tage-Chart
OSSDSIGN AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,3121,33615:15
1,3221,32815:05

Aktuelle News zur OSSDSIGN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
OSSDSIGN Aktie jetzt für 0€ handeln
DiOSSDSIGN AB: Exercise period starts in OssDsign's long-term incentive warrant program 2022/2025, boosting the company's cash position by up to SEK 10 million18
MoKarolinska Development AB (publ): Karolinska Development divests shares in portfolio company OssDsign127STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company's...
► Artikel lesen
DoOssDsign AB: OssDsign announces remarkable real-world results with 88.4% fusion rate in a highly complex patient cohort from the spinal fusion registry PROPEL122Uppsala, June 26, 2025. OssDsign AB (publ.) today announces that the company has published one-year results from the first 108 patients in its prospective, multi-center, spinal fusion registry PROPEL....
► Artikel lesen
11.06.Annual General Meeting held in OssDsign AB22
09.06.OSSDSIGN AB: Revised proposal for election of the board of directors in OssDsign22
04.06.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets10STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding...
► Artikel lesen
03.06.OSSDSIGN AB: OssDsign has carried out a directed share issue of approximately SEK 158 million15
03.06.OSSDSIGN AB: OssDsign explores the conditions for increasing the scope of the directed share issue to approximately 11.5 million shares5
03.06.OSSDSIGN AB: OssDsign explores the conditions to carry out a directed share issue and announces an updated strategy and revised financial targets4
14.05.OSSDSIGN AB: OssDsign included in MSCI index13
14.05.OSSDSIGN AB: OssDsign publishes Annual Report 20248
13.05.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US2
12.05.NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB2
12.05.OssDsign AB: 10,000 patients treated with OssDsign Catalyst in the U.S.168Uppsala, May 12, 2025. Today, OssDsign AB (publ.) announces that it has reached its milestone of 10,000 patients treated with the innovative nanosynthetic bone graft, OssDsign Catalyst, confirming its...
► Artikel lesen
06.05.OssDsign AB: OssDsign AB (publ) publishes Q1 2025 interim report85Strong growth and best operating result everOssDsign AB (publ) announces that the interim report for Q1 2025 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version...
► Artikel lesen
30.04.Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign will change CEO during second half of 20253
30.04.OssDsign AB: OssDsign announces CEO transition planned for the second half of 202585Uppsala, April 30, 2025. OssDsign® AB (publ.) today announces that Morten Henneveld will step down as CEO at the end of the year to support the establishment of leadership with an even stronger presence...
► Artikel lesen
11.04.OSSDSIGN AB: Groundbreaking Study Highlights Enhanced Bone Formation with Novel Silicate-Containing Synthetic Bone Grafts12
09.04.OSSDSIGN AB: 24-month follow up data from the clinical study of OssDsign Catalyst® show 100% spinal fusion3
25.02.OSSDSIGN AB: OssDsign reaches its target of 300 patients enrolled in the prospective spinal fusion registry PROPEL7
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2